KWM
NVAX icon

Kingsview Wealth Management’s Novavax NVAX Stock Holding History

Kingsview Wealth Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,943
Closed -$564K – 968
2021
Q4 		$564K Buy
3,943
+185
+5% +$31.8K 0.02% 542
2021
Q3 		$779K Buy
+3,758
New +$828K 0.04% 443

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kingsview Wealth Management's NVAX Position: Q1 2022 in Review

Kingsview Wealth Management sold out of Novavax (NVAX) in Q1 2022, closing a stake of 3,943 shares — an estimated $564K sold.

Kingsview Wealth Management first reported a position in NVAX in Q3 2021 and held it in 2 quarters. The position peaked at $779K in Q3 2021. 381 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

  • Kingsview Wealth Management reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
  • Kingsview Wealth Management sold 3,943 Novavax shares in Q1 2022, an estimated $564K.
  • Kingsview Wealth Management first reported a position in Novavax in Q3 2021 and held it in 2 quarters.
  • Kingsview Wealth Management's Novavax position peaked at $779K in Q3 2021.
  • 381 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on Kingsview Wealth Management's 13F filing for Q1 2022, filed 8 Feb 2024.